Company / Capital Expenditures
Insight Molecular Diagnostics Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$516.0K
FY2025
5-year range
$281.0K / $4.3M
FY2021-FY2025
Trend
+83.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $4M to $516,000 over the past 2 years.
Based on SEC 10-K filings.
$516,000 in FY2025 with a 5-year CAGR of -10.9%.
Declined from $4M to $516,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -38.8%
- 5-Year CAGR
- -10.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.9%, indicating a declining trend.
- In FY2025, capital expenditures increased 83.6% year-over-year.
- Peak capital expenditures was recorded in FY2023.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $516.0K | +83.6% |
| FY2024 | $281.0K | -93.5% |
| FY2023 | $4.3M | +93.1% |
| FY2022 | $2.2M | +83.1% |
| FY2021 | $1.2M | +33.7% |
| FY2020 | $918.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026